Similis-Blau biosimilars development partnership announced

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Similis-Blau biosimilars development partnership announced

Home/Pharma News | Posted 04/11/2022 0 Post your comment

On 25 October 2022, JSR Life Sciences (and LLC (JSR)) have announced that their recently launched biosimilars development branch, Similis Bio, has signed a development and license agreement with Brazilian firm, Blau Farmacêutica.

The agreement is a multi-year deal to develop products and license IP for four biosimilar products targeting indications in oncology, inflammation and blood disorders. The products that these molecules will reference have not been disclosed. Blau and Similis noted that the addressable market for these biosimilars is US$42 billion globally and close to US$1 billion in Brazil, according to IQVIA.

Under the terms of the partnership, Similis Bio will provide full processes and associated IP for tech transfer to Blau, including cell lines, analytical data and methodologies, and upstream/downstream processes. In turn, Blau will utilize the licensed IP for good manufacturing practice (GMP) manufacturing and clinical development and be the entity to seek regulatory approval.

Blau will have exclusive rights to the products and intends to have them authorized in both North and South America. The agreement between Blau and Similis includes upfront payments and long-term royalties upon commercial approval for sale. The partners have divulged that they expect the total value of the contract to exceed US$100 million.

Roberto Morais, executive director in charge of mergers and acquisitions and strategic alliances at Blau Farmacêutica, said, ‘We are developing products for the next decade, and we will further add new products to our partnership. This strategic and disruptive agreement reinforces Blau's position in becoming a reference in the production of biosimilars in Latin America’.

As of July 2022, it is reported that Brazil has approved 46 biosimilars, with more being considered for approval by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA). These are within the product classes of: 1) insulin; 2) monoclonal antibodies; 3) tumour necrosis factor (TNF) inhibitor; 4) human growth hormone; 5) anticoagulants and heparins; and 6) granulocyte colony stimulating-factor. The first biosimilar approved in Brazil was Remsima (CT-P13), an infliximab’s biosimilar, in April 2015 [1].

Related articles
Pharmaceutical manufacturing companies in Brazil

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: La provincia canadiense de Saskatchewan introduce una política de switching de biosimilares

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: La provincia canadiense de Saskatchewan introduce una política de switching de biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Nov 4]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-brazil

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.